NCT06470763
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06470763
Title A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1)
Acronym EXPAND-1
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Anaveon AG
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NLD | FRA | ESP | DEU | CHE | BEL

Facility Status City State Zip Country Details
Karmanos Cancer Institute Detroit Michigan 48201 United States Details
Fox Chase Cancer Center Philadelphia Pennsylvania 19111 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
Cliniques Universitaires Saint-Luc Brussels Belgium Details
Institut Bergonie Bordeaux France Details
CEPCM - AP-HM Hopital de la Timone Marseille France Details
Oncopole Claudius Regaud, Toulouse Toulouse France Details
Institut Gustave Roussy Villejuif France Details
Charite Universitaetsmedizin Berlin Berlin Germany Details
Krankenhaus Nordwest - Institut für Klinisch-Onkologische Forschung (IKF) Frankfurt Germany Details
Universitaetsmedizin der Johannes Gutenberg - Universitaet Mainz Mainz Germany Details
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL) Amsterdam Netherlands Details
Vall d'Hebron Institute of Oncology (VHIO) Barcelona Spain Details
START Madrid CIOCC Madrid Spain Details
Clinica Universidad de Navarra - Pamplona Pamplona Spain Details
INCLIVA Foundation Valencia Spain Details
Ente Ospedaliero Cantonale - Istituto Oncologico della Svizzera Italiana Bellinzona Switzerland Details
Cantonal Hospital St Gallen Sankt Gallen Switzerland Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field